Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280677 | 1.00 | TSHR (0.50) | TSHRCYP1A2CYP2C19KDM4EKDM1A | |
| SCHEMBL1477389 | 1.00 | TSHR (0.50) | TSHRCYP1A2CYP2C19KDM4EKDM1A | |
| SCHEMBL22209851 | 1.00 | TSHR (0.50) | TSHRCYP1A2CYP2C19KDM4EKDM1A | |
| SCHEMBL12749371 | 1.00 | TSHR (0.50) | TSHRCYP1A2CYP2C19KDM4EKDM1A | |
| SCHEMBL23020647 | 0.86 | CYP1A2 (0.48) | TSHRCYP1A2CYP2C19KDM4EATM | |
| SCHEMBL12749374 | 0.86 | CYP1A2 (0.48) | TSHRCYP1A2CYP2C19KDM4EATM | |
| SCHEMBL1477579 | 0.86 | CYP1A2 (0.48) | TSHRCYP1A2CYP2C19KDM4EATM | |
| SCHEMBL13591320 | 0.86 | CYP1A2 (0.48) | TSHRCYP1A2CYP2C19KDM4EATM | |
| SCHEMBL4467918 | 0.86 | CYP1A2 (0.48) | TSHRCYP1A2CYP2C19KDM4EATM | |
| SCHEMBL12749381 | 0.83 | HPGD (0.49) | TSHRCYP1A2CYP2C19KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915295-B2 | Viricides; HIV antivirals effective against problematic drug escape mutants; N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| EP-1701942-B1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2009-12-09 | — | — | EP | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1701942-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| WO-2005066131-A1 | NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6610714-B2 | HIV viricides | MEDIVIR AB (SE) | 2003-08-26 | — | — | US | disclosed |
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092743-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SUB1, HCFC1, CCR1 | TSHR 2282/4885CYP1A2 1007/4885CYP2C19 1460/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | TSHR 1578/4885CYP1A2 1896/4885CYP2C19 1753/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | TSHR 367/4885CYP1A2 1035/4885CYP2C19 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.